A £1.65m hope for blood disorder patients is now on offer in Manchester
A £1.65 million treatment has been approved for use for some NHS patients, offering hope of a cure to those with an inherited blood disorder. Campaigners have shared their joy as health officials approved a gene-editing therapy for certain children and adults with severe sickle cell disorder.
It is estimated that 1,700 people could be eligible after the National Institute for Health and Care Excellence (Nice) approved Casgevy for certain patients with the genetic condition. NHS officials estimate that around 50 people a year will receive treatment.
Casgevy, also known as exa-cel, was the first treatment to be licensed using gene-editing tool Crispr, which earned its inventors the Nobel Prize for chemistry in 2020. It works by editing the faulty gene in a patient's own stem cells.
READ MORE: Suspect named and set to face court following alleged M6 pursuit
READ MORE: Knifeman left friend fighting for his life following unexplained attack
Cells are taken from a patient to a laboratory where the Crispr technology is used. The edited cells are then infused back into the patient, which prompts the body to produce healthy red blood cells.
The only curative treatment currently available for people with sickle cell in the UK is a donor stem cell transplant. But it is not given to many patients due to the risks involved.
Casgevy is an option for patients when a stem cell transplant is suitable but no donor can be found. In March last year, Nice rejected Casgevy for people with severe sickle cell disease.
Nice said it required more information on the drug's effectiveness and a commercial agreement, with its £1.65 million list price.
Now, a confidential deal has now been struck with its creators, Vertex, on how much the NHS will pay for the treatment under a "managed access scheme".
Nice has endorsed the treatment for some people aged 12 and over who suffer from "recurrent vaso-occlusive crises" and have a specific genotype. Dr Samantha Roberts, Nice's chief executive, said: "Exa-cel could represent a potential cure for some people with severe sickle cell disease, freeing people from the burden of complications as well as addressing Nice's aim of reducing health inequalities associated with the condition and getting the best care to patients fast."
Ludovic Fenaux, senior vice president at Vertex International, celebrated the announcement, saying: "Today is an important day for the sickle cell community who have gone too long without treatments that address the underlying cause of their devastating disease."
In the UK, approximately 17,500 individuals live with sickle cell disease, which is particularly common among those with African or Caribbean heritage. The disease can lead to intense pain, life-threatening infections, and anaemia.
Mehmet Tunc Onur Sanli, 42, from London, who has been battling sickle cell disease since he was diagnosed at age 11, explained: "Because of my illness, I often experience pain in my chest, bones, and muscles.
"I had surgery on my spleen when I was six and a hip replacement at 22 – I will probably need another hip replacement in the next few months or years.
Speaking about the frequency and severity of his sickle cell crises, he said: "I also suffer from regular sickle cell crises – last year, I had to go to the hospital at midnight after waking up in severe pain, and overall, I had to visit the hospital five or six times due to crises."
"The pain is the worst I have ever felt in my life – it's hard to put into words."
'Not having to go to hospital for regular transfusions or taking medicine anymore would be a dream to me – gene therapy could offer that – but there's still a lot to consider in terms of the side effects that could come with this treatment and whether it would be the right choice for me.'
In clinical trials, all patients who received exa-cel also avoided hospital admission for a year following treatment – and almost 98% had still avoided being admitted to hospital around 3.5 years later.
The treatment will be offered at specialist NHS centres in London, Manchester and Birmingham.
NHS England chief executive Amanda Pritchard said: 'This is a leap in the right direction for people with sickle cell disease – which can be an extremely debilitating and painful condition.
'This innovative, gene-editing therapy offers hope of a cure for people facing a severe form of the disease and could be absolutely transformative – it could enable patients to live free from the fear of sickle cell crises hanging over them.
'We are funding this new treatment option straight away so patients can benefit from the enhanced quality of life it offers.'
John James, chief executive of the Sickle Cell Society, said: 'We are absolutely thrilled to see this groundbreaking gene therapy treatment available on the NHS from today.
'The significance of this milestone for the sickle cell community cannot be understated – today's result will give hope to many and is the result of determined campaigning.'
The Medicines and Healthcare products Regulatory Agency (MHRA) approved the treatment in November 2023 for patients aged 12 and over after a 'rigorous assessment of its safety, quality and effectiveness'.
It was the first regulator in the world to approve the treatment.
Yasmin Sheikh, head of policy and public affairs at Anthony Nolan, said: 'This groundbreaking decision to fund the UK's first ever Crispr-based therapy for patients with sickle cell disorder represents a leap forward in the treatment of this debilitating and life-threatening condition.
'Previously, only individuals fortunate enough to have a stem cell donor match could access stem cell transplants as a potential cure.
'With Casgevy, we now have a treatment that offers hope to more patients, the majority of whom are from African and African-Caribbean backgrounds and have experienced years of feeling ignored.
'This treatment has the potential to transform lives and offers a glimpse into the exciting possibilities of gene therapy.'
Nice approved the treatment for certain patients with a severe form of the blood disorder thalassemia in August last year.
The NHS spending watchdog said that it will collect more data while patients receive the treatment on the NHS before it evaluates the medicine again.
It said that collecting more data through a managed access agreement may resolve some uncertainty in the evidence, particularly about how long the benefits of treatment with exa-cel last.
Health minister Andrew Gwynne said: 'By offering a treatment that could allow patients to live a life free of debilitating illness, we will give people with conditions like sickle cell disease more freedom and independence, all whilst protecting vital NHS emergency services.'
Professor Bob Klaber, director of strategy, research and innovation at Imperial College Healthcare NHS Trust – which led the UK arm of the clinical trials for exa-cel, said: 'Together with patients and industry partners, we are proud to be part of the ground-breaking research and international academic collaboration that has made this treatment possible.
'The treatment is an example of true medical innovation and will provide patients with no other options a potential cure for the painful, debilitating symptoms of their diseases.
'It also offers promising research avenues for other genetic diseases.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Write, submit an idea, learn: Don't wait or hold back, just do it
We often imagine that the people who achieve great things in life – whether in science, art, or any field of impact – do so only when everything is in place. When they feel ready. When they have the resources. When confidence arrives like a green light. But that's rarely the case. If you wait until you feel fully skilled, fully prepared, fully sure – you'll be waiting forever. Because readiness isn't a moment that arrives before action. It's something that is built through action. The truth is, nobody has it all figured out from the start. Not even the ones who changed the world. Take Marie Curie. When she first began her groundbreaking research on radioactivity, she worked in what could barely be called a laboratory – just a leaky, unheated shed behind a school in Paris. Her equipment was rudimentary, her working conditions far from ideal. But she started anyway. Slowly, painstakingly, she uncovered the elements polonium and radium, and changed the course of science forever. She didn't wait to be invited into the halls of recognition. She walked in with curiosity and courage, even when everything around her said, not yet. Or consider Paul Lauterbur and Peter Mansfield, awarded the 2003 Nobel Prize in Physiology or Medicine for their work on magnetic resonance imaging (MRI). When Lauterbur first proposed his idea of spatial encoding of MRI signals – basically tracking movements of water molecules in our body under changing magnetic fields – he was told by several peers that the concept wouldn't work. His initial paper was even rejected by academic journals. But he didn't stop. He kept refining, experimenting, pushing forward. Peter Mansfield, working independently in the UK, added mathematical precision and practical applications to Lauterbur's vision. Together, through trial, failure, and persistence – not certainty – they helped create a medical breakthrough that has saved millions of lives. No one handed them a perfect roadmap. They began with what they had and allowed the process to show them the rest. The same is true of the Wright brothers. Neither Wilbur nor Orville had formal engineering training. They were bicycle mechanics with an obsession for flight. When they began designing their first aircraft, they had no guarantees. What they did have was a workshop, a windy field, and an unshakable willingness to try. And fail. And try again. On Dec 17, 1903, after years of trial and error, they achieved powered flight. What united these individuals wasn't certainty – it was movement. Because progress doesn't come from waiting for the perfect moment. It comes from doing what you can with what you have. From taking the first step, even when the second is unclear. That's where clarity comes from. That's where confidence begins – not before action, but after you begin. But too often, we let hesitation wear the mask of wisdom. We say we're preparing. Planning. Waiting for 'the right time.' But behind that delay often lives fear. Fear of getting it wrong. Fear of judgment. Fear of being seen before we feel complete. Yet what's worse than failing is never starting at all. Perfection is a seductive illusion. It convinces us that we need one more certificate, one more tool, one more dose of courage before we begin. But all perfection really does is delay progress. Because messy beginnings still move you forward. The first draft is always rough. The early stages of anything – be it a project, a paper, a plan – are supposed to feel shaky. That's not failure. That's momentum. Even in technology and research, we rarely launch with a finished product. Software goes live in beta. Hypotheses evolve mid-experiment. Scientific understanding is always, by nature, iterative. So why should we expect our personal or creative pursuits to be perfectly formed from the outset? Start before you feel ready. That's not recklessness. It's wisdom wrapped in action. Because here's the truth: you cannot think your way into certainty. But you can act your way into it. Each step you take reveals the next. Each small effort sharpens your direction. And over time, the fear that once held you back gets replaced by something far more valuable: belief in your ability to adapt. So if you've been holding back – waiting to feel smarter, braver, richer, more experienced – consider this your permission to begin. With shaky hands. With limited resources. With uncertainty still in the air. Start writing the thing. Submit the idea. Try the method. Take the class. Launch the version you have now. Imperfect action beats perfect procrastination every single time. Just stop waiting. The views expressed here are the personal opinion of the writer and do not necessarily represent that of Twentytwo13.
Yahoo
12 hours ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool
Newsweek
13 hours ago
- Newsweek
French Scientists Discover New Blood Group
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A group of French researchers have discovered a new, "ultra rare" blood group in a Guadeloupean woman after years of researching and sequencing her blood, the French Blood Establishment (EFS) said in a Friday press release. Newsweek has reached out to EFS's press team for comment via email on Saturday. Why It Matters The discovery marks the 48th known blood group system in the world. Understanding blood types is critical for ensuring safe and effective transfusions and organ transplants, as well as identifying certain health risks. Blood classification helps medical providers determine compatibility—or lack thereof—between donors and recipients. There are approximately 14 million units of blood transfused annually in the United States, according to the U.S. Centers for Disease Control and Prevention (CDC). Outside of the well-known ABO system, there are a series of rare blood groups. What To Know In a social media post on LinkedIn, the EFS said in French that "this discovery was officially recognized in early June in Milan by the International Society of Blood Transfusion (ISBT)." The woman is the only known carrier of a rare blood type called "Gwada negative." The case first drew attention in 2011 when she required a blood transfusion, but no compatible donor could be found. Researchers later revisited her case in 2019 and identified the unique blood type through further analysis, according to the EFS's Friday press release. Thierry Peyrard, a medical biologist at the EFS involved in the discovery, told Agence France-Presse (AFP) that a "very unusual" antibody was found in the patient's blood in 2011. She was 54 years old at the time when she underwent a series of tests prior to surgery, according to Le Monde. Due to limited resources at the time, research into her blood type had been halted. Peyrard said the woman inherited the blood type from her parents who had the mutated gene. EFS, in French, said that the discovery "brings hope to patients, especially those with a rare blood type. Remember that the safety of a transfusion depends on the compatibility of blood groups." The group says it has been responsible for identifying 10 of the past 17 blood group systems discovered in the past decade. Karl Landsteiner discovered the first blood groups in the early 1900s and was awarded the Nobel Prize in 1930 for his work. Serum tubes with blood samples from patients are processed in the central medical laboratory of the St. Georg Clinic in Leipzig. Serum tubes with blood samples from patients are processed in the central medical laboratory of the St. Georg Clinic in Leipzig. Waltraud Grubitzsch/picture-alliance/dpa/AP Images What People Are Saying The official Nobel Prize account posted on X, formerly Twitter, on June 17: "The discovery of blood groups completely changed the view on blood transfusions, and it didn't take long before the first successful attempts were carried out. During WWI, blood transfusions were first performed on a large scale. Countless lives were also saved through surgeries, which previously had been unfeasible due to the blood loss involved." What Happens Next? Scientists continue to study blood types, advancing global health care and improving the precision and effectiveness of transfusions.
